Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement
June 03, 2024 00:41 ET
|
Burning Rock Biotech Limited
Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement
AMD Unveils Next-Gen “Zen 5” Ryzen Processors to Power Advanced AI Experiences
June 02, 2024 23:01 ET
|
Advanced Micro Devices, Inc.
— AMD Ryzen™ AI 300 Series Processors Unlock Transformational AI Experiences for Windows Copilot+ PCs — — AMD Ryzen™ 9000 Series Processors Set New Standards in Efficiency, Performance, and Content...
AMD Accelerates Pace of Data Center AI Innovation and Leadership with Expanded AMD Instinct GPU Roadmap
June 02, 2024 23:00 ET
|
Advanced Micro Devices, Inc.
— Updated AMD Instinct accelerator roadmap brings annual cadence of leadership AI performance and memory capabilities — — New AMD Instinct MI325X accelerator expected to be available in Q4 2024...
AMD Extends AI and High-Performance Leadership in Data Center and PCs with New AMD Instinct, Ryzen and EPYC Processors at Computex 2024
June 02, 2024 22:59 ET
|
Advanced Micro Devices, Inc.
— Expanded AMD Instinct accelerator roadmap brings annual cadence of leadership AI accelerators; next generation AMD EPYC processors to extend data center CPU leadership — — New AMD Ryzen AI 300...
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
June 02, 2024 20:38 ET
|
Immutep Limited
Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC)TACTI-004 Phase III trial...
Mesoblast Corporate Presentation at Investor Conference
June 02, 2024 20:23 ET
|
Mesoblast Limited
NEW YORK, June 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference. Dr....
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
June 02, 2024 20:00 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that results from FRUTIGA,...
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
June 02, 2024 19:00 ET
|
Caribou Biosciences, Inc.
-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER...
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
June 02, 2024 12:30 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative,...
Merus : présentation des données provisoires sur le MCLA-145 en monothérapie et en association avec le pembrolizumab lors du congrès annuel 2024 de l’ASCO®
June 02, 2024 12:30 ET
|
Merus N.V.
UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 02 juin 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), ci-après « Merus, la Société, nous, ou notre », une société spécialisée dans...